Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
CONCLUSIONS: Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the BRCA promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in BRCA. PMID: 29404838 [PubMed - as supplied by publisher]
CONCLUSION: Treosulfan might be an effective and well-tolerated treatment even in heavily pre-treated patients with metastatic breast cancer. PMID: 29767877 [PubMed - in process]
The authors regret that upper (#1) and bottom (#4) pictures were mistakenly identical in normal and ovarian cancer patient's tissues in Fig. 1C. The authors would like to apologise for any inconvenience caused.
Abstract Knoevenagel condensation of 3,4-dichloro- and 2,6-dichloro- phenylacetonitriles gave a library of dichlorophenylacrylonitriles. Our leads 5 and 6 displayed 0.56±0.03 and 0.127±0.04 μM growth inhibition (GI₅₀) and 260-fold selectivity for the MCF-7 breast cancer cell line. A 2,6-dichlorophenyl moiety saw a 10-fold potency loss; additional nitrogen moieties (-NO₂) enhanced activity (26 and 27), with the corresponding -NH₂ analogues (29 and 30) more potent. Despite this, both 29 (2.8±0.03 μM) and 30 (2.8±0.03 μM) were 10-fold less cytotoxic than 6. A bromine moiet...
TPIV200 stimulates T cells to attack ovarian and triple negative breast tumor cells that over-express the folate receptor alpha protein.
CONCLUSION: Regarding limited evidence patients with oligometastatic disease origin from non-gastrointestinal tumors could benefit from liver resection. Tumor biology and response to targeted individualized systemic therapy become more important in this scenario. PMID: 29767820 [PubMed - as supplied by publisher]
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Conclusions: Among long-term TNBC survivors, the rate of referral to genetic counseling increased over time, and among those tested, 35% carried a BRCA pathogenic variant. Survivorship care provides an excellent opportunity to refer eligible patients for genetic counseling. PMID: 29752326 [PubMed - in process]
Conclusions: Our study shows that the ASMRs of breast, cervical, and ovarian cancer remain high in Singapore compared to Japan and Korea. Generally speaking, the mortality risk of three cancers increased with age, and period and cohort effects may collectively affect the common female malignances mortality for East Asian women. PMID: 29750160 [PubMed - in process]
Human breast cancer (BC) is the most common cancer among women in US and worldwide, with 2.4 million new cases diagnosed in 2015 [1,2]. It is the second most common cause of death from cancer in women in US, with estimated deaths of 40,610 in 2017 . The large percentage ( ∼70%) of BC are endocrine-related and ovarian sex hormone estrogen is regarded as both initiator and promoter of BC [3–6]. Another ovarian sex hormone progesterone and its metabolites are also considered to promote BC [7,8]. The BC expressing estrogen receptors (ER) and/or progesterone receptors (PR) responds to hormone therapy .
In conclusion, our data demonstrated that miR-520d-3p antitumor activity is achieved by targeting the SKA2 in human breast cancer cells, suggesting that miR-520d-3p may be a potential target molecule for the therapy. PMID: 29736203 [PubMed]